Mar 14, 2018 by Brian Orelli, PhDIs Gilead Sciences Trying to Put Itself Out of Business?A new treatment brings the biotech one step closer to an HIV cure.
Mar 13, 2018 by Brian Orelli, PhDWhy Exelixis Fell 14.9% in FebruarySlowing growth has investors worried.
Mar 12, 2018 by Brian Orelli, PhDCantel Medical Reports a Solid Quarter While Saying Thanks to Uncle SamManagement is increasing guidance, with help from lower tax rates.
Mar 12, 2018 by Brian Orelli, PhDGenomic Health Hits its Inflection PointThere's no turning back now.
Mar 8, 2018 by Brian Orelli, PhDWhy Progenics Pharmaceuticals Jumped 15.2% on ThursdayAn FDA decision is imminent.
Mar 8, 2018 by Brian Orelli, PhDWhy Celldex Therapeutics Shot Up TodayInvestors pile in ahead of a binary event.
Mar 7, 2018 by Brian Orelli, PhDWhy Clearside Biomedical Is Up for a Third Straight DayThe drugmaker is raising capital at very little cost.
Mar 6, 2018 by Brian Orelli, PhDWhy Clearside Biomedical Jumped Higher TodayAfter positive clinical trial data yesterday, a regulatory update on the company's other trials keeps the momentum going.
Mar 5, 2018 by Brian Orelli, PhDWhy Vericel Jumped Higher TodayIt was a solid fourth quarter for the biotech, with more revenue growth expected in 2018.
Mar 1, 2018 by Brian Orelli, PhDWhy an FDA Approval Caused Sorrento Therapeutics' PainA sell-the-news 24% drop. Oh my!
Mar 1, 2018 by Brian Orelli, PhDMore Commercial Revenue on Its Way for Ionis PharmaceuticalsThe biotech has two drugs under regulatory review, and a pipeline of 45 drugs advancing towards commercialization.
Mar 1, 2018 by Brian Orelli, PhDHere's Why Corium International Sank TodayA capital raise and a regulatory update have investors hitting the sell button.
Feb 28, 2018 by Brian Orelli, PhDDiplomat Pharmacy Thinks Its Strategy Is a "Huge Game Changer"The company needs to show that combining pharmacy benefit management and specialty pharmacy services works.
Feb 27, 2018 by Brian Orelli, PhDExelixis in TransitionThe biotech posted a disappointing quarter, but there's more growth ahead.
Feb 27, 2018 by Brian Orelli, PhDWhy Diplomat Pharmacy Sank TodayInvestors fret after the company reports fourth-quarter results.
Feb 26, 2018 by Brian Orelli, PhDBioMarin Turns a Profit (on an Adjusted Basis)It's a step in the right direction for the 20-year old biotech.
Feb 26, 2018 by Brian Orelli, PhDEmergent BioSolutions Gets its Deals Done (and Expect More to Come)Newly acquired products and contracts will help revenue growth accelerate in 2018.
Feb 23, 2018 by Brian Orelli, PhDHere's Why Adamas Pharmaceuticals Dropped TodayInvestors fret over the launch of the biotech's new Parkinson's disease drug Gocovri.
Feb 22, 2018 by Brian Orelli, PhDbluebird bio Updates Plans for the Year AheadThe gene therapy company is on the precipice of applying for approval for its first drug.
Feb 22, 2018 by Brian Orelli, PhDMomenta Pharmaceuticals Wraps Up a Bleak YearChoices will have to be made on how to fund its promising pipeline.
